A phase <scp>II</scp> trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: <scp>SARC024</scp> trial results-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results

Published:2022-08-10 Issue:2 Volume:12 Page:1532-1539
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Attia Steven¹,Bolejack Vanessa²,Ganjoo Kristen N.³,George Suzanne⁴,Agulnik Mark⁵,Rushing Daniel⁶,Loggers Elizabeth T.⁷,Livingston Michael B.⁸,Wright Jennifer⁹¹⁰,Chawla Sant P.¹¹,Okuno Scott H.¹²,Reinke Denise K.¹³^ORCID,Riedel Richard F.¹⁴,Davis Lara E.¹⁵^ORCID,Ryan Christopher W.¹⁵,Maki Robert G.¹⁶^ORCID

Affiliation:

1. Mayo Clinic Jacksonville Jacksonville Florida USA

2. Cancer Research and Biostatistics Seattle Washington USA

3. Stanford Cancer Institute Stanford California USA

4. Dana‐Farber Cancer Institute/Brigham and Women's Hospital Boston Massachusetts USA

5. City of Hope Duarte California USA

6. Indiana University Bloomington Indiana USA

7. Fred Hutchinson Cancer Research Center Seattle Washington USA

8. Levine Cancer Institute Charlotte North Carolina USA

9. Huntsman Cancer Institute Salt Lake City Utah USA

10. Lilly Pharmaceuticals Indianapolis Indiana USA

11. Sarcoma Oncology Center Santa Monica California USA

12. Mayo Clinic Rochester Minnesota USA

13. Sarcoma Alliance for Research through Collaboration Ann Arbor Michigan USA

14. Duke Cancer Institute Durham North Carolina USA

15. Oregon Health & Science University Portland Oregon USA

16. Abramson Cancer Center, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

Funder

Bayer HealthCare

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5044

Reference27 articles.

1. Sarcomas More Common in Children

2. Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience

3. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

4. Cyclophosphamide and Topotecan as First-line Salvage Therapy in Patients With Relapsed Ewing Sarcoma at a Single Institution

5. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data;Cancers;2024-01-08

2. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study;British Journal of Cancer;2023-11-01

3. Real‐world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study;Cancer Medicine;2023-09

4. Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers;Oncogene;2023-05-02

5. Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas;American Society of Clinical Oncology Educational Book;2023-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3